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Abstract
Background: Endoglin is involved in the regulation of endothelial function, but there are no studies concerning its
relation with hypertension- and diabetes-associated pathologies. Thus, we studied the relationship between plasma
levels of soluble endoglin and cardiovascular alterations associated with hypertension and diabetes.
Methods: We analyzed 288 patients: 64 with type 2 diabetes, 159 with hypertension and 65 healthy patients. We
assessed the relationship of soluble endoglin plasma levels measured by enzyme-linked immunosorbent assay with
basal glycemia, glycosylated hemoglobin, blood pressure, endothelial dysfunction (assessed by pressure wave
velocity), hypertensive retinopathy (by Keith-Wagener classification), left ventricular hypertrophy (by Cornell and
Sokolow indexes), cardiovascular risk and target organ (heart, vascular, kidney) damage.
Results: There are significant correlations between endoglin and glycemia, systolic blood pressure, pulse pressure,
pressure wave velocity and electrocardiographically assessed left ventricular hypertrophy. Endoglin levels were
significantly higher in patients with diabetes who had nondipper and extreme dipper circadian blood pressure
patterns than in dipper circadian patterns, in patients with hypertension and diabetes who had riser pattern than
in the other patients, and in patients with diabetes but not hypertension who had extreme dipper pattern than in
dipper, nondipper and riser groups. There was also a significant correlation between plasma-soluble endoglin and
lower levels of systolic night-day ratio. Higher endoglin levels were found in patients with diabetes who had
retinopathy, in patients with diabetes who had a high probability of 10-year cardiovascular risk, and in patients
with diabetes and hypertension who had three or more damaged target organs (heart, vessels, kidney) than in
those with no organs affected.
Conclusions: This study shows that endoglin is an indicator of hypertension- and diabetes-associated vascular
pathologies as endothelial dysfunction and cardiovascular damage.
Background
Vascular disease is the main cause for disability and
death in patients with diabetes mellitus [1]. In type 2
diabetes, small vessels (microangiopathy) or large vessels
(macroangiopathy) are affected. Microvascular disease is
characteristic of several pathologies such as retinopathy,
nephropathy, neuropathy and impaired wound healing,
whereas diabetic macroangiopathy is detected by
accelerated atherosclerosis and damages vital organs
such as heart and brain, being responsible for the
increased risk of myocardial infarction, stroke and
lower-limb amputation [2,3]. The initial lesion of athero-
sclerosis involves changes in the vascular endothelium
[4], and patients with diabetes invariably show an
impairment of endothelium-dependent vasodilation,
which is partly due to the frequent association of the
disease with other cardiovascular risk factors, including
hypertension, obesity and dyslipidemia [5]. The term
endothelial dysfunction refers to a condition in which
the endothelium loses its physiological properties and
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proinflammatory state [3]. The fundamental feature of
this condition is the impaired nitric oxide (NO) bioavail-
ability that can be the consequence of either a reduced
production by endothelial nitric oxide synthase (eNOS)
or an increased removal by reactive oxygen species [6].
Hyperglycemia, insulin resistance, hyperinsulinemia and
dyslipidemia independently contribute to endothelial
dysfunction through different mechanisms, but increased
oxidative stress seems to be the first alteration triggering
several others [3].
Endoglin (also known as CD105), a type I transmem-
brane glycoprotein highly expressed on proliferating vas-
cular endothelial cells (ECs) [7], has been identified as
an accessory receptor for transforming growth factor-b
(TGF-b) [8]. It is expressed as a 180-kDa homodimer
formed by disulfide-linked monomers [9]. The human
endoglin gene has been localized to chromosome
9q34ter [10], and it is mutated in the Rendu-Osler-
Weber syndrome or hereditary hemorrhagic telangiecta-
sia type 1 (HHT1) [11]. Mice lacking endoglin die
during the embrionary phase due to defective angiogen-
esis [12], and endoglin plays a major role in tumoral
and nontumoral adult angiogenesis [13,14]. A soluble
form of endoglin also plays a central role in preeclamp-
sia, a disease characterized by hypertension and severe
alterations in placental circulation [15]. Overall, these
data support the view that endoglin has a pivotal func-
tion in vascular development and disease [13].
Endoglin is expressed at low levels in resting ECs, but
it is highly expressed in vascular ECs during embryogen-
esis [16], in inflamed tissues and healing wounds [17],
psoriatic skin [18], inflamed synovial arthritis [19], upon
vascular injury [20] and in tumor vessels [7,13] and in
the proliferating endothelium of tissues undergoing
angiogenesis [13]. Endoglin is expressed in ECs and in
several other cell types involved in the cardiovascular
system. For example, while endoglin expression is low in
normal smooth muscle cells [21], its expression is upre-
gulated in vascular smooth muscle cells of human ather-
osclerotic plaques [22]. Endoglin is also expressed in
cardiac fibroblasts and modulates the profibrogenic
actions of angiotensin II [23].
A soluble form of endoglin (Sol-endoglin) has been
detected in plasma, serum and urine from patients with
pathologies such as preeclampsia and cancer, and its
peptide sequence suggests that it is an N-terminal clea-
vage product of full-length, membrane-bound endoglin
[15]. Uterine ischemia and/or hypoxia play a major role
in increased Sol-endoglin release [24]. In addition to
being a reliable biomarker of the disease, it has been
suggested that Sol-endoglin plays a major role as an
antiangiogenic factor in preeclampsia [25]. A possible
mechanism involved in the antiangiogenic effects of Sol-
endoglin is based on its inhibitory effect on TGF-b1-
mediated eNOS activation in ECs [15]. In vitro studies
have demonstrated that Sol-endoglin impairs EC prolif-
eration and capillary formation [15]. Sol-endoglin also
seems to be a regulator of vascular tone, as administra-
tion of Sol-endoglin to mice induces an increase in
arterial pressure by increasing vascular resistance [15].
Thus, Sol-endoglin seems to impair endothelial function,
and endothelial dysfunction is a major characteristic of
patients with diabetes.
We have assessed the relationship between plasma
levels of Sol-endoglin and vascular alterations associated
with diabetes, specifically blood pressure, endothelial
dysfunction, retinopathy, degree of left ventricular
hypertrophy, cardiovascular risk and target organ
damage in patients with type 2 diabetes and hyperten-
sion compared to control patients of similar age.
Methods
This is a cross-sectional study performed in patients
with diabetes with or without hypertension. Patients
enrolled in the study over a period of 24 months (from
January 2008 to January 2010) were from the Internal
Medicine Section, University Hospital of Salamanca, and
from the Primary Care Research Unit of La Alamedilla
Health Centre (Castilla y León Health Service-SACYL),
Salamanca, Spain, which covers a population of 46,000
inhabitants. Altogether, 288 consecutive patients com-
plied with the inclusion or exclusion criteria and were
asked to participate in the study. Groups of patients
were as follows: 64 patients with diabetes (42 of them
were hypertensive) and 159 patients with hypertension
but not diabetes. Sixty-five healthy individuals were
selected as a control group.
Inclusion criteria were patients diagnosed with dia-
betes mellitus 2 and/or hypertension and aged 20-80
years, with none of the following exclusion criteria:
patients unable to comply with the protocol require-
ments (psychological and/or cognitive disorders, failure
to cooperate, educational limitations and problems in
understanding written language, and failure to sign the
informed consent document), patients participating or
who were going to participate in a clinical trial during
the study, and patients with serious comorbidities repre-
senting a threat to life. Most of the patients with hyper-
tension and diabetes received drug therapy (except
those controlled by diet), which is described in Table 1.
Hypertension was diagnosed when the mean of three
separate measurements of blood pressure over time was
≥ 140 mmHg for systolic blood pressure (SBP) and/or ≥
90 mmHg for diastolic blood pressure (DBP). At each
measurement, blood pressure was measured at least
twice, separated by more than 1 minute, as recom-
mended by The Task Force for the Management of
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tension and of the European Society of Cardiology [26].
Diabetes was diagnosed when fasting glucose level was ≥
126 mg/dL or ≥ 200 mg/dL 2 hours after oral glucose
overload (repeated on two occasions) or after detection
of symptoms of diabetes and random blood glucose ≥
200 mg/dL as recommended by the Expert Committee
on the Diagnosis and Classification of Diabetes Mellitus
[27].
Ethical and legal issues
The experimental protocol was in accordance with the
Declaration of Helsinki (2000) of the World Medical
Association and also was in agreement with the guide-
lines of and approved by the Ethics Committee of the
University Hospital of Salamanca, Spain, and complied
with Spanish data protection law 15/1999 and its devel-
oped specifications (RD 1720/2007). Each patient
included in the study signed an informed consent form
to participate in the study after full explanation of the
purpose and nature of all procedures used. To guarantee
data confidentiality, all the electronic and paper copies
of the protocol, signed informed consent documents
and results of the tests were kept locked in a safe place,
and only the study investigators had access to the data
on the people who agreed to participate in the study.
Sociodemographic and cardiovascular variables
We evaluated the next sociodemographic variables and
cardiovascular risk factors: patient age and sex, hyper-
tension, dyslipidemia, alcohol consumption, smoking,
physical activity and history of premature cardiovascular
disease (before 55 years of age in males and before 65 in
females) in first-degree relatives, myocardial infarction,
angina, revascularization, heart failure, atrial fibrillation
and cerebrovascular events (ischemic stroke, intracranial
haemorrhage and transient brain ischemia), as well as
the presence of symptomatic peripheral arterial disease.
Anthropometric measurements
Body weight was determined at two different times
using a homologated electronic scale (Seca 770; Seca,
Hamburg, Germany) following due calibration (precision
± 0.1 kg), with the patient wearing light clothing and
without shoes. Readings were rounded to 100 g. Height
was measured with a portable system (Seca 222), record-
ing the average of two readings, and with the patient
shoeless in the standing position. The values were
rounded to the closest centimeter. Body mass index
(BMI; measured in kilograms per meter squared) was
also calculated. Waist circumference was measured
using a flexible, graduated measuring tape with the
patient in the standing position without clothing. The
upper border of the iliac crests was located, and the
tape was wrapped just above this point without com-
pressing the skin. The reading was taken at the end of a
normal breath according to the recommendations of the
2007 SEEDO Conference [28].
Biochemical determinations
Blood samples were collected in the morning, after the
patient had fasted for at least 8 hours prior to other mea-
surements. Physiological determinations were creatinine,
basal glucose and glycosylated hemoglobin (HbA1c),
high-density lipoprotein (HDL) cholesterol, low-density
lipoprotein (LDL) cholesterol, total cholesterol and
Table 1 Drug therapies administered in patients with hypertension and/or diabetes
Total DIA without HYP DIA with HYP HYP without DIA
Antihypertensive drugs (%) 47.21 100.00 58.19
Diuretics (%) 41.67 50.00 43.26
ACEi (%) 39.58 43.75 33.65
ARB (%) 34.03 40.00 35.58
b-blockers (%) 29.86 31.25 32.69
a-blockers (%) 5.56 7.50 2.88
Calcium antagonists (%) 18.06 23.75 18.27
Other antihypertensive drugs (%) 1.39 0.00 1.92
Antidiabetic drugs (%) 21.987 84.38 87.50
Insulin (%) 20.90 29.63 20.00
Metformin (%) 83.58 85.19 80.00
Sulfonylureas (%) 32.84 14.81 37.14
Meglitinides (%) 2.99 7.41 4.29
a-glucosidase inhibitors (%) 1.49 1.43
Glitazones (%) 7.14
Data are expressed as percentages. ACEi, angiotensin-converting enzyme inhibitors; ARB, angiotensin receptor blockers; DIA, patients with diabetes; HYP, patients
with hypertension.
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meters were measured on a blind basis in a General Hos-
pital Biochemistry laboratory using standard
authomatized techniques.
Blood pressure determination
Office blood pressure evaluation involved three mea-
surements of SBP and DBP using the average of the last
two measurements, with a validated OMRON model
M7 sphygmomanometer (Omron Health Care, Kyoto,
Japan), following the recommendations of the European
Society of Hypertension [29]. Pulse pressure was esti-
mated with the mean values of the second and third
measurements.
Home blood pressure was self-measured using an
OMROM model M7 sphygmomanometer as previously
described [30]. Patients were apprised of how to per-
form blood pressure recordings at home, and educa-
tional leaflets were developed to ensure that the patients
correctly performed these self-measurements. A self-
registry sheet was provided to ensure correct pressure
recording.
Ambulatory blood pressure monitoring was performed
on a standard activity day, with a SpaceLabs 90207
model (Spacelabs Healthcare, Issaquah WA, USA), vali-
dated according to the protocol of the British Hyperten-
sion Society [31]. Records in which the percentage of
valid readings was ≥ 66% of the total measurements
were considered to be valid. Furthermore, a 24-hour
ambulatory blood pressure monitoring device was fitted.
At least 14 measurements (every 20 min) during the
daytime or at least 7 measurements (every 30 min) dur-
ing the nighttime or resting period were required. The
average and dispersion estimators of SBP and DBP were
calculated along 24 h, including daytime and nighttime
periods, on the basis of the diary reported by the
patient, in which bedtime and wakeup time were
specified.
Evaluation of peripheral artery disease
Peripheral artery disease (PAD) was evaluated in the
morning using the ankle-brachial index (ABI), with the
patient having refrained from consuming caffeine-con-
taining beverages and alcohol, and not having smoked,
in the previous 12 h, and with room temperature ran-
ging between 22°C and 24°C. With the feet uncovered
and in a supine decubitus position after resting for 20
min, pressure in the lower extremities was measured
using a portable Doppler system Minidop Es-100Vx
(Hadeco Inc., Miyamae-ku Kawasaki, Japan) applying
the probe at the anterior or posterior tibial artery at an
angle of approximately 60° to blood flow direction.
Blood pressure was also measured twice at 3- to 5-
minute intervals in both arms. ABI was calculated as
previously described [32]. Subclinical PAD was diag-
nosed if ABI was lower than 0.9 [33].
Identification of left ventricular hypertrophy
Electrocardiographic (ECG) examination was performed
with a General Electric MAC 3.500 ECG System
(Niskayuna NY, USA), which measures voltage and
duration of waves and estimates the criteria of the Cor-
nell voltage duration product (Cornell VDP) [34] to
assess left ventricular hypertrophy (LVH) using the fol-
lowing equations: (RaVL + SV3) × QRS in men and
(RaVL + SV3) × QRS + 6 in women. LVH was defined
as the VDP value greater than 2,440 mV/ms [26]. LVH
was also determined as the next voltage sum: S wave in
V1 + R wave in lead V5 or V6 ≥ 35 mm using Sokolow-
Lyon voltage criteria [35].
Renal function assessment
Kidney damage was assessed by measuring plasma
creatinine concentrations, glomerular filtration rate was
estimated by CKD-EPI (Chronic Kidney Disease Epide-
miology Collaboration) [36] and the MDRD-IDMS
(Modification of Diet in Renal Disease-Isotopic Dilu-
tion Mass Spectrometry) [37] formulas, and proteinuria
was assessed using the albumin-creatinine ratio follow-
ing the 2007 European Society of Hypertension/
European Society of Cardiology Guidelines criteria
[26]. Subclinical organ damage was defined as plasma
creatinine between 1.3 and 1.5 mg/dL in men and 1.2
and 1.4 mg/dL in women, glomerular filtration rate
below 60 ml/min or albumin-creatinine ratio > 22 mg/
g in men and 31 mg/g in women. Renal disease was
defined as plasma creatinine of 1.5 mg/dL or higher in
men or 1.4 mg/L in women or albumin-creatinine ratio
> 300 mg/24 h.
Evaluation of retinopathy
Retinography was performed with a Topcon TRC NW
200 nonmydriatic retinal camera (Topcon Europe B.C.,
Capelle a/d Ijssel, The Netherlands), obtaining images
centered on the papilla. Captured images were classified
by two independent observers according to the Keith-
Wagener classification for hypertensive retinopathy [38].
Retinopathy was classified as grade I (generalized arter-
iolar constriction), grade II (irregularly located, tight
constrictions), grade III (retinal edema, cotton-wool
spots and flame haemorrhages, sclerosis and spastic
lesion of arterioles, hard exudates including a macular
star) and grade IV (same as grade III but with swelling
of the optic disk and silver wiring). Grade III or IV was
considered to be associated with cardiovascular disease
[26].
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of pulse wave velocity
Pulse wave velocity (PWV) was calculated in the morn-
ing (between 8:30 and 11:00 AM) 1-2 days before blood
was drawn, using the SphygmoCor System (Vx Pulse
Wave Velocity; AtCor Medical, West Ryde, Australia)
with patients in supine decubitus position [39]. This
analysis was performed in a blinded fashion by the same
trained researcher who was completely unaware of the
health status of the patients analyzed. Carotid and
femoral pulse waves were analyzed, estimating the delay
in the ECG wave and calculating the PWV. Space mea-
surements were taken with a measuring tape from the
suprasternal notch to the carotid and femoral arteries at
the sensor location. A measurement of PWV higher
than 12 m/s was considered endothelial dysfunction
[26].
Pulse wave analysis was performed with a sensor in
the radial artery using mathematical transformations to
estimate the aortic pulse wave with the SphygmoCor
system (Px Pulse Wave Analysis), with patients in sitting
position and resting the arm on a rigid surface. The aor-
tic wave morphology was used to estimate central (aor-
tic) arterial pressure along with central ventricular load,
diastolic perfusion pressure, subendocardial viability
index, pressure increment, central pulse pressure and
the augmentation index (PWA), defined as the percen-
tage of the increase in central pulse pressure: AIx =
pressure increase × 100/pulse pressure [40].
Cardiovascular risk assessment
Cardiovascular risk of patients was assessed using the
scale of the ESH-ESC guide 2007 [26]. Risk categories
were average risk (adjusted for age and sex), low added
risk, moderate, high or very high risk.
Plasma soluble endoglin determination
Sol-endoglin concentration in plasma samples was eval-
uated using an enzyme-linked immunosorbent assay
method (Human Endoglin; R&D Systems, Minneapolis,
MN, USA) following the instructions of the manufac-
turer. With regard to specificity, the assay recognizes
recombinant and human endoglin without significant
cross-reactivity or interference with other members of
the TGF-b family. With regard to sensitivity, the mini-
mum detectable dose ranged from 0.001 to 0.030 ng/
mL. Absorbance (proportional to the initial amount of
endoglin) was determined using a spectrophotometer
(Thermo Luminoscan Ascent, Waltham, MA, USA) at
450 nm with a wavelength correction of 540 nm.
Statistical analysis
Data input was performed using the Teleform system
(Autonomy Cardiff, Vista, CA, USA) and exporting the
data to the PASW version 18.0 statistical package (SPSS
Inc., Chicago, IL, USA) for data analysis. Data followed
a normal distribution as confirmed by kurtosis normality
of residuals test. Data were presented as means ± stan-
dard error of the mean (SEM) or standard deviation in
the case of quantitative variables, and as frequency dis-
tributions for qualitative variables. The c
2 test was used
to analyze associations between qualitative variables.
Student’s t-test was used for independent samples to
compare quantitative variables for two groups, and one-
way analysis of variance was used for more than two
groups. Pearson’s correlation test was used to analyze
associations between quantitative variables. A P value
lower than 0.05 was considered statistically significant.
Owing to our sample size (288 patients), our low varia-
bility and the selected a value (0.05), the power of our
study is 0.95 (b value, 0.05).
Results
General and medical characteristics of the patients are
presented in Table 2; 46.23% of patients presented over-
weight (BMI > 25 kg/m
2) and 32.13% of patients were
obese (BMI > 30 kg/m
2) (Table 2).
Endoglin and diabetes
In our study population, there was a positive correlation
between Sol-endoglin plasma levels and basal glycemia
in patients with diabetes and hypertension and between
endoglin levels and glycated hemoglobin in all patients
with diabetes (Table 3).
Endoglin and blood pressure
There was a significant correlation between plasma Sol-
endoglin concentration and SBP (in both office evalua-
tion and home self-measurement) in patients with
diabetes and hypertension and in all patients with
hypertension with or without diabetes (Table 3). There
was also a strong correlation between pulse pressure
and Sol-endoglin plasma levels in patients with diabetes,
either with or without hypertension (Table 3). Further-
more, endoglin levels were different depending on the
circadian blood pressure pattern. Thus, endoglin levels
were higher in all patients with diabetes with nondipper
(absence of the normal nocturnal fall in blood pressure)
and extreme dipper (with marked nocturnal blood pres-
sure falls) than in dipper circadian patterns (Figure 1A).
Endoglin levels were also higher in patients with hyper-
tension and diabetes with riser circadian pattern (noc-
turnal blood pressure increase compared with daytime
blood pressure) than in the other patients (Figure 1B).
Moreover, nonhypertensive patients with diabetes with
extreme dipper pattern showed higher plasma levels of
Sol-endoglin than did dipper, nondipper and riser
groups (Figure 1C), and endoglin showed a negative
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(Table 3). On the other hand, we also observed a posi-
tive correlation between heart rate and plasma Sol-
endoglin in nonhypertensive patients with diabetes
(Table 3).
Endoglin and endothelial dysfunction
Endothelial dysfunction was evaluated by the analysis of
PWV, which indicates arterial stiffness. Our study show
that plasma Sol-endoglin levels showed a positive
correlation with PWV values in patients with hyperten-
sion and diabetes (Table 3).
Endoglin and retinopathy
We found a strong relation between Sol-endoglin
plasma levels and retinopathy. Higher endoglin levels
(above 5 ng/mL) were found in all patients with diabetes
(odds ratio, 4.72) and in patients with hypertension and
diabetes (odds ratio, 3.54) categorized as grade III and
grade IV in the Keith-Wagener retinal changes
Table 2 Demographic, physical and medical characteristics of the patients included in the study
Total DIA without HYP DIA with HYP HYP without DIA Controls
Number 288 22 42 159 65
Age (yr) 54.90 ± 11.68 53.27 ± 12.74 62.17 ± 8.03 56.69 ± 11.08 48.75 ± 11.22
Male sex (%) 62.29 81.81
a 66.67
a 62.78 53.85
Body mass index (kg/m2) 28.32 ± 4.26 28.71 ± 4.99 30.33 ± 4.86 28.68 ± 3.93 26.82 ± 3.29
Endoglin (ng/mL) 5.04 ± 1.05 5.02 ± 0.98 4.88 ± 1.20 4.39 ± 1.04 5.21 ± 1.10
Basal glycemia (mg/dL) 98.76 ± 30.77 121.22 ± 30.03
b,e 132.56 ± 45.52
b,e 88.45 ± 11.49 84.47 ± 9.04
HbA1c (%) 5.42 ± 1.05 6.72 ± 1.07
b,e 6.80 ± 1.30
b,e 5.03 ± 0.45 4.91 ± 0.45
Systolic blood pressure (mmHg) 125.89 ± 12.72 121.34 ± 8.37 126.20 ± 14.21
c 127.03 ± 13.94
c 123.69 ± 9.52
Diastolic blood pressure (mmHg) 77.05 ± 9.43 73.38 ± 6.08 72.78 ± 9.11
a,d 76.82 ± 9.88
c 77.65 ± 7.65
Heart rate (beats/min) 71.96 ± 10.56 75.11 ± 11.29 72.51 ± 10.28 71.08 ± 11.06
c 72.77 ± 10.31
Leukocytes (10
3 cells/μL) 6.70 ± 1.95 7.35 ± 2.90
a 7.23 ± 1.94
a 6.71 ± 1.96
a 6.08 ± 1.03
Neutrophils (10
3 cells/μL) 3.52 ± 1.33 4.06 ± 2.30
a 3.76 ± 1.32
a 3.52 ± 1.25 3.17 ± 0.93
Lymphocytes (10
3 cells/μL) 2.41 ± 0.74 2.49 ± 0.61 2.71 ± 0.77 2.42 ± 0.83 2.23 ± 0.52
Monocytes (10
3 cells/μL) 0.54 ± 0.26 0.56 ± 0.19 0.58 ± 1.18 0.55 ± 0.32 0.47 ± 0.15
Eosinophils (10
3 cells/μL) 0.21 ± 0.22 0.19 ± 0.10 0.24 ± 0.17 0.23 ± 0.28 0.18 ± 0.11
Basophils (10
3 cells/μL) 0.04 ± 0.03 0.04 ± 0.02 0.03 ± 0.02 0.04 ± 0.03 0.03 ± 0.03
Smokers (%) 24.92 36.36 16.67 26.81 24.61
High-density lipoproteins (mg/dL) 52.35 ± 12.42 46.27 ± 8.85
a,d 47.43 ± 9.74
a,d 53.50 ± 12.41 54.13 ± 13.51
Low-density lipoproteins (mg/dL) 125.80 ± 32.67 113.72 ± 27.18
a 105.63 ± 25.52
a,d 131.43 ± 34.14
c 127.13 ± 28.74
Alcohol consumption (U/wk) 11.30 ± 20.33 9.79 ± 15.82 12.70 ± 20.94 12.21 ± 23.45 10.15 ± 18.06
Daily physical activity (%) 34.75 31.82 57.14
a 34.78 26.15
FPACD (%) 15.08 9.09 30.95
a,c,d 13.77 9.23
Data are expressed as means ± standard deviation or percentage. DIA, patients with diabetes; HbA1c, glycosylated hemoglobin; HYP, patients with hypertension;
FPACD, family premature antecedents of cardiovascular disease in first-degree relatives.
aStatistically significant differences (P < 0.05) vs. control group;
bP <
0.0001 vs. control group;
cP < 0.05 vs. DIA without HYP;
dP < 0.05 vs. HYP without DIA;
eP < 0.0001 vs. HYP without DIA.
Table 3 Pearson’s correlations between plasma endoglin and basal glycemia, glycated hemoglobin and cardiovascular
parameters
All DIA R P value DIA without HYP
R P value
DIA with HYP
R P value
All HYP
R P value
HYP without DIA
R P value
Control
R P value
Basal glycemia 0.221 0.079 -0.230 0.304 0.360 0.019
a 0.065 0.388 -0.130 0.128 -0.095 0.451
Glycated hemoglobin 0.257 0.042
a 0.347 0.114 0.239 0.132 0.008 0.912 -0.118 0.167 -0.097 0.451
Systolic blood pressure 0.243 0.053 -0.072 0.751 0.381 0.013
a 0.183 0.031
a 0.009 0.918 -0.076 0.547
Pulse pressure 0.326 0.009
a -0.150 0.506 0.519 0.000
a 0.118 0.115 -0.024 0.784 0.064 0.611
Systolic night-day ratio -0.109 0.391 -0.481 0.019
a 0.037 0.817 -0.033 0.665 -0.063 0.468 0.009 0.946
Heart rate 0.053 0.678 0.508 0.016
a -0.141 0.374 -0.054 0.474 -0.023 0.788 -0.232 0.064
Pulse wave velocity 0.194 0.127 -0.131 0.562 0.348 0.026
a 0.009 0.905 -0.096 0.262 -0.144 0.251
VDP Cornell 0.382 0.002
a 0.273 0.219 0.439 0.004
a 0.148 0.047
a 0.027 0.752 -0.171 0.174
Sokolow index 0.223 0.076 0.127 0.575 0.294 0.058 0.151 0.043
a 0.093 0.281 0.071 0.575
DIA, diabetic patients; HYP, hypertension; R, correlation coefficient; VDP, voltage-duration product.
aStatistically significant differences (P < 0.05).
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Figure 1 Comparison of Sol-endoglin plasma levels and circadian blood pressure pattern. (A) Patients with diabetes. (B) Patients with
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Page 7 of 12classification, in both right and left eyes compared with
patients with grades I and II (Figure 2).
Endoglin and left ventricular hypertrophy
LVH was evaluated by electrocardiography using both
Cornell and Sokolow indexes. We observed positive
correlations between plasma Sol-endoglin levels and
Cornell-VDP in patients with hypertension as well as in
all patients with diabetes (Table 3). There was also a
positive correlation between endoglin levels and Soko-
low index in patients with hypertension (Table 3).
Endoglin, cardiovascular risk and target organs damage
We observed that plasma Sol-endoglin levels were higher
in patients with hypertension and diabetes and in all
patients with diabetes with very high cardiovascular risk
in the next 10 years compared with patients with mild
vascular risk. Although we have not found any significant
relationship or correlation between Sol-endoglin and
renal dysfunction, endoglin levels were higher in patients
with diabetes with three or more target organs damaged
than in those with no organs affected (Figure 3).
Discussion
Our data shows that Sol-endoglin plasma levels are sig-
nificantly related to glycemia, SBP, pulse pressure, PWV,
heart rate and the degree of LVH assessed by ECG. Sol-
endoglin plasma levels are different in patient groups
depending on the circadian blood pressure pattern, and
increased endoglin levels are associated with retinopa-
thy, very high 10-year cardiovascular risk and increased
number of damaged target organs in patients with type
2 diabetes. This is the first study in humans showing
that plasma Sol-endoglin concentration could serve as
an indicator of diabetes-associated pathologies such as
hypertension, endothelial dysfunction and cardiovascular
risk. It should be noted that a high correlation coeffi-
cient has been obtained between plasma Sol-endoglin
levels and heart rate (0.508; P = 0.016), and this is espe-
cially important as heart rate has been recently sug-
gested to be a marker of increased vascular risk [41].
Sol-endoglin seems to be a regulator of vascular tone.
We show that Sol-endoglin levels are higher in patients
with diabetes who have increased levels of SBP; accord-
ing to our findings, in an experimental model with preg-
nant rats, Gilbert et al. [24] showed that placental
ischemia increases the expression of Sol-endoglin and
provokes hypertension, thus mimicking the pathophysio-
logic features of preeclampsia. Moreover, overexpression
of Sol-endoglin in rodents was found to induce hyper-
tension and increased vascular permeability [42]. It has
been shown that injection of Sol-endoglin into rats
induced hypertension [15]. Recent studies from our
group have shown that transgenic mice overexpressing
human Sol-endoglin are hypertensive (unpublished
results). To explain the mechanism involved, it has been
proposed that Sol-endoglin induces its prohypertensive
effects through interaction with circulating endoglin-
binding molecules, such as the TGF-b protein superfam-
ily, thus preventing the binding of these molecules to
the TGF-b receptor complex [25].
The relevance of endoglin in the cardiovascular system
is reflected by the fact that mutations in the endoglin
gene cause a vascular disease called the Rendu-Osler-
Weber syndrome or HHT1 [11], which is characterized
by vascular dysplasia, frequent episodes of epistaxis,
mucocutaneous telangiectases and arteriovenous malfor-
mations of the lung, brain, liver and gastrointestinal
tract [43]. A reduction in Sol-endoglin levels has been
recently described in patients with HHT1 [44]. About
15%-35% of HHT patients show pulmonary arteriove-
nous malformations, 10% have cerebral arteriovenous
malformations, 25%-33% suffer significant gastrointest-
inal blood loss from gastrointestinal tract telangiectasia
and an unknown but high percentage have liver involve-
ment. In summary, 10% of HHT patients die prema-
turely or experience major disability, largely because of
bleeding or paradoxical embolization through pulmon-
ary or cerebral arteriovenous malformations [45]. Ocular
manifestations include conjunctival, retinal and
Figure 2 Comparison of Sol-endoglin plasma levels and Keith-
Wagener retinal grades III and IV classification. (A) Patients with
hypertension and diabetes. (B) All patients with diabetes. Data (ng/
mL) are expressed as means ± SEM. One-way ANOVA: *P < 0.05 (A)
and P < 0.01 (B).
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Page 9 of 12choroidal telangiectasia [46]. Although it has been
recently shown that the loss of endoglin leads to retinal
vascular abnormalities in mice [47], the frequency of
ocular manifestation in patients with HHT is estimated
to be 1.9% for retinal involvement [46]. The prevalence
of cardiovascular disease other than that mentioned
above in patients with HHT1 does not seem to be
higher than in the general population when adjusted by
other endoglin-independent risk factors [43]. Neverthe-
less, the results obtained in our study seem to suggest
that S-endoglin levels are associated with cardiovascular
damage, which does not mean that they are themselves
the cause of such damage.
It has been reported that administration of Sol-endoglin
to mice elevates arterial pressure by increasing vascular
resistance [15]. Most probably, this effect could be attribu-
ted to the inhibitory effect of Sol-endoglin on TGF-b1-
mediated eNOS activation in ECs, and it has been sug-
gested that high levels of circulating Sol-endoglin could
contribute to the hypertension shown by women with pre-
eclampsia [15].
As previously described, the impairment of endothe-
lium-dependent vasodilation in patients with diabetes is
due to the impaired NO bioavailability [6], and endoglin
expression and NO regulation are intimately related, as we
have demonstrated that endoglin plays a major role in reg-
ulating eNOS abundance and NO synthesis regulation
based on two different mechanisms. First, endoglin regu-
lates eNOS mRNA expression [48-50]. The second
mechanism is the regulation of eNOS protein half-life and
eNOS activity [51]. Mice deficient in endoglin (eng
+/-)
show a defective vasodilatorr e s p o n s et oe n d o t h e l i u m -
dependent vasodilator substances such as acetylcholine or
bradykinin [48]. In agreement with these data, eng
+/- mice
show a decreased NO synthesis and a decreased eNOS
expression [48,49,51]. TGF-b1 leads to an increased vaso-
dilation in control mice that is severely impaired in eng
+/-
mice, suggesting the involvement of endoglin in the TGF-
b-regulated vascular homeostasis [50].
Changes in Sol-endoglin plasma levels have been
reported in other pathologies different from preeclamp-
sia, such as atherosclerosis and coronary artery disease
[52]. Also, changes of Sol-endoglin plasma levels after
an acute myocardial infarct are accurate predictors of
acute mortality in these patients [53]. Although there
are numerous reports on the possible participation of
Sol-endoglin in different diseases, the specific molecular
mechanism of action of this soluble form of endoglin in
these pathologies remains to be elucidated. In pree-
clampsia, the origin of Sol-endoglin seems to be the
destruction of the placental vessels and/or the shedding
of membrane-bound endoglin by specific membrane
metalloproteases [25]. In the case of patients with
diabetes and/or hypertension, we do not know what the
origin of the increased plasma Sol-endoglin levels is.
Limitations of our study are its cross-sectional design,
which precludes longitudinal analysis between endoglin,
cardiovascular risk factors and subclinical organ damage,
and the selection of the study population, since sam-
pling was performed consecutively with pragmatic and
broad inclusion criteria, including patients with hyper-
tension with a recent diagnosis or short course of hyper-
tension, patients with diabetes and hyperlipidemia, and
many patients receiving drug therapy. This could modify
blood pressure levels and therefore limit the validity of
some results. Consequently, the heterogeneity of the
sample could lead to some limitations when interpreting
the results, though it is quite similar to the distribution
of the real population of short-course patients with
hypertension who have some risk factors and without
previous cardiovascular disease.
Conclusions
Endoglin expression has revealed its prognostic and
diagnostic value in other circumstances, being a poten-
tial vascular target for antiangiogenic cancer therapy
[13]. Our study shows the emerging role of endoglin as
an indicator of diabetes-associated vascular pathologies
such as hypertension, endothelial dysfunction and cardi-
ovascular risk. While much more work must be done to
fully understand the molecular mechanisms that under-
lie the role of endoglin in these pathologies, this study
provides new research strategies for better diagnosis,
prognosis and therapy in diabetes-associated endothelial
dysfunction. These results are innovative and relevant
enough to start prospective studies that will allow us to
establish the relative strength of the prediction of cardi-
ovascular risk and the appearance of target organ
damage according to the endoglin levels presented by
the patient.
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